Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History AMPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics AMPH

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Amphastar P

AMPH
Current price
22.21 USD -0.23 USD (-1.02%)
Last closed 22.44 USD
ISIN US03209R1032
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 1 093 627 136 USD
Yield for 12 month -43.30 %
1Y
3Y
5Y
10Y
15Y
AMPH
21.11.2021 - 28.11.2021

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Address: 11570 6th Street, Rancho Cucamonga, CA, United States, 91730

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

32.40 USD

P/E Ratio

8.41

Dividend Yield

Financials AMPH

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures AMPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+712 814 000 USD

Last Year

+644 395 000 USD

Current Quarter

+170 528 000 USD

Last Quarter

+186 523 000 USD

Current Year

+373 855 000 USD

Last Year

+351 121 000 USD

Current Quarter

+85 251 000 USD

Last Quarter

+86 648 000 USD
EBITDA 248 295 008 USD
Operating Margin TTM 21.87 %
Price to Earnings 8.41
Return On Assets TTM 7.60 %
PEG Ratio 2.77
Return On Equity TTM 19.90 %
Wall Street Target Price 32.40 USD
Revenue TTM 730 659 008 USD
Book Value 15.76 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -0.80 %
Dividend Yield
Gross Profit TTM 369 006 016 USD
Earnings per share 2.76 USD
Diluted Eps TTM 2.76 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -37.00 %
Profit Margin 19.38 %

Stock Valuation AMPH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 8.41
Forward PE
Enterprise Value Revenue 2.07
Price Sales TTM 1.50
Enterprise Value EBITDA 5.82
Price Book MRQ 1.46

Technical Indicators AMPH

For 52 Weeks

22.64 USD 53.96 USD
50 Day MA 24.71 USD
Shares Short Prior Month 4 096 720
200 Day MA 34.92 USD
Short Ratio 8.26
Shares Short 4 080 346
Short Percent 17.15 %